Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
30
09
2019
revised:
09
01
2020
accepted:
07
02
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
It is unclear which radiotherapy technique and dose fractionation scheme is most effective in decreasing the risk of prostate cancer death. We conducted a population-based cohort study among 15 164 men in the Prostate Cancer database Sweden (version 4.0) treated with primary radical radiotherapy for prostate cancer in Sweden from 1998 to 2016. We calculated hazard ratios with 95% confidence intervals (CIs) of the association between the following exposure groups and outcome: conventionally fractionated external beam radiotherapy (EBRT) to 78 Gy (39 × 2 Gy), EBRT combined with high dose-rate brachytherapy (HDR-BT) (25 × 2 Gy + 2 × 10 Gy), conventionally fractionated EBRT to 70 Gy (35 × 2 Gy), and moderately hypofractionated (M-HF) dose-escalated EBRT (29 × 2.5 Gy or 22 × 3 Gy). Of the men, 7296 received conventionally fractionated EBRT to 78 Gy, 4657 EBRT combined with HDR-BT, 1672 conventionally fractionated EBRT to 70 Gy, and 1539 M-HF EBRT. Using EBRT to 78 Gy as the reference, the multivariable hazard ratios (95% CIs) of prostate cancer death was 0.64 (0.53 to 0.78) for EBRT combined with HDR-BT, 1.00 (0.80 to 1.27) for EBRT to 70 Gy, and 1.51 (0.99 to 2.32) for M-HF EBRT. The multivariable hazard ratios (95% CIs) for death from any cause were 0.79 (0.71 to 0.88), 0.99 (0.87 to 1.14), and 1.12 (0.88 to 1.42), respectively. The lower risk of prostate cancer death comparing EBRT combined with HDR-BT with conventionally fractionated EBRT to 78 Gy was more pronounced for men with high-risk or poorly differentiated tumors. In this study, EBRT combined with HDR-BT was the most effective radiotherapy treatment regimen, especially for poorly differentiated tumors. Randomized trials comparing EBRT combined with HDR-BT with dose-escalated EBRT should be a priority.
Sections du résumé
BACKGROUND
BACKGROUND
It is unclear which radiotherapy technique and dose fractionation scheme is most effective in decreasing the risk of prostate cancer death.
METHODS
METHODS
We conducted a population-based cohort study among 15 164 men in the Prostate Cancer database Sweden (version 4.0) treated with primary radical radiotherapy for prostate cancer in Sweden from 1998 to 2016. We calculated hazard ratios with 95% confidence intervals (CIs) of the association between the following exposure groups and outcome: conventionally fractionated external beam radiotherapy (EBRT) to 78 Gy (39 × 2 Gy), EBRT combined with high dose-rate brachytherapy (HDR-BT) (25 × 2 Gy + 2 × 10 Gy), conventionally fractionated EBRT to 70 Gy (35 × 2 Gy), and moderately hypofractionated (M-HF) dose-escalated EBRT (29 × 2.5 Gy or 22 × 3 Gy).
RESULTS
RESULTS
Of the men, 7296 received conventionally fractionated EBRT to 78 Gy, 4657 EBRT combined with HDR-BT, 1672 conventionally fractionated EBRT to 70 Gy, and 1539 M-HF EBRT. Using EBRT to 78 Gy as the reference, the multivariable hazard ratios (95% CIs) of prostate cancer death was 0.64 (0.53 to 0.78) for EBRT combined with HDR-BT, 1.00 (0.80 to 1.27) for EBRT to 70 Gy, and 1.51 (0.99 to 2.32) for M-HF EBRT. The multivariable hazard ratios (95% CIs) for death from any cause were 0.79 (0.71 to 0.88), 0.99 (0.87 to 1.14), and 1.12 (0.88 to 1.42), respectively. The lower risk of prostate cancer death comparing EBRT combined with HDR-BT with conventionally fractionated EBRT to 78 Gy was more pronounced for men with high-risk or poorly differentiated tumors.
CONCLUSIONS
CONCLUSIONS
In this study, EBRT combined with HDR-BT was the most effective radiotherapy treatment regimen, especially for poorly differentiated tumors. Randomized trials comparing EBRT combined with HDR-BT with dose-escalated EBRT should be a priority.
Identifiants
pubmed: 32373776
doi: 10.1093/jncics/pkaa006
pii: pkaa006
pmc: PMC7192027
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkaa006Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63
pubmed: 21147514
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
JAMA Oncol. 2018 Jun 14;4(6):e180039
pubmed: 29543933
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285
pubmed: 28262473
Int J Epidemiol. 2016 Feb;45(1):73-82
pubmed: 26659904
J Clin Oncol. 2008 May 20;26(15):2497-504
pubmed: 18413638
Lancet Oncol. 2014 Apr;15(4):464-73
pubmed: 24581940
JAMA. 2018 Mar 6;319(9):896-905
pubmed: 29509865
Radiother Oncol. 2012 May;103(2):217-22
pubmed: 22341794
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1012-7
pubmed: 22981709
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Eur Urol. 2017 Nov;72(5):738-744
pubmed: 28688613
J Clin Oncol. 2017 Jun 10;35(17):1891-1897
pubmed: 28355113
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865
pubmed: 29485063
JAMA Oncol. 2015 Oct;1(7):897-906
pubmed: 26181727
Scand J Urol Nephrol. 2008;42(4):352-7
pubmed: 18609293
J Clin Oncol. 2018 Oct 10;36(29):2914-2917
pubmed: 29782208
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e17-24
pubmed: 21324610
J Clin Oncol. 2018 Oct 10;36(29):2943-2949
pubmed: 30106637
J Clin Oncol. 2013 Nov 1;31(31):3860-8
pubmed: 24101042
Brachytherapy. 2019 May - Jun;18(3):313-321
pubmed: 30846330
J Clin Oncol. 2010 Mar 1;28(7):1106-11
pubmed: 20124169
JAMA. 2008 Jan 23;299(3):289-95
pubmed: 18212313
Am J Clin Oncol. 2018 Apr;41(4):409-415
pubmed: 27014930
Radiother Oncol. 2019 Mar;132:211-217
pubmed: 30389241
J Clin Oncol. 2018 Apr 20;36(12):1192-1198
pubmed: 29489433
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90
pubmed: 15817329
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):790-797
pubmed: 30836166
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):90-93
pubmed: 28816169
Radiother Oncol. 2014 Jan;110(1):104-9
pubmed: 24246414
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
N Engl J Med. 2011 Jul 14;365(2):107-18
pubmed: 21751904